Update on Bondlido’s U.S. sales partnership and listing timing outlook. Expectation of contract signing in September and a change to the listing timing to the fourth quarter of 2026. Reassessment of sales conditions and revenue-sharing remains uncertain during the period. Impact on the FY2026 earnings guidance is unclear, but will be disclosed promptly as soon as determined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4576","jir_company_name":"De Westan Therapitechs Institute","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4576-20260831-01.pdf","jir_short_summary":"Update on Bondlido's U.S. sales partnership and listing timing outlook. Expectation of contract signing in September and a change to the listing timing to the fourth quarter of 2026. Reassessment of sales conditions and revenue-sharing remains uncertain during the period. Impact on the FY2026 earnings guidance is unclear, but will be disclosed promptly as soon as determined.","jir_summary":"### Section heading\nThis material explains the latest status of Bondlido's U.S. sales partnership and listing timing. It outlines the progress of reconsidering the joint development with MedRx and the sales partnership terms with Terrain Pharmaceuticals, reasons for the contract signing delay, and changes to the current listing timing. Revisions to contract terms are taking time, and while a sales license agreement is expected to be signed in September, an acceleration is unlikely. The listing timing has not changed to the fourth quarter of 2026.\n\n### Section 2 heading\nBondlido's U.S. revenue outlook remains uncertain, with potential contingent revenue distributions depending on contract terms, but impact on the FY2026 earnings forecast remains uncertain. Future decisions and changes to contract terms will be promptly disclosed, and sales strategy and supply plans will continue to be reviewed.","jir_financial_highlights":"Receipt of contingent revenue distribution based on Bondlido's revenue: Unknown (Unknown)\nListing timing: Fourth quarter 2026 expected adjustment (Changed)\nSigning date of the sales license agreement: September expectation (Delay)","jir_category":"","jir_hashtags":"#Bondlido, #USSalesPartnership, #BusinessUpdate","jir_key_figures":"Possibility of revenue distribution from Bondlido\nDelay in signing the Sales License Agreement (September expectation)\nConfirmation of listing timing change to the fourth quarter of 2026","jir_meta_title":"\u3010De Westan Therapitechs Institute\u3011Bondlido U.S. sales partnership and listing timing latest trends | August 2026","jir_meta_description":"Key points on Bondlido's U.S. sales partnership and listing timing. Explains delays in contract signing, listing timing revisions, and potential revenue impact uncertainties; further details to be disclosed upon contract finalization.","jir_og_title":"Bondlido U.S. sales partnership and listing timing latest trends","jir_og_description":"Updates on Bondlido's U.S. sales partnership and listing timing. Explains reconsideration of contract terms and expected changes to listing timing, with planned future disclosures.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59943,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-108655","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n